184 filings
6-K
NBTX
Nanobiotix
16 May 24
Voting Rights and Shares Capital of the Company
4:15pm
6-K
NBTX
Nanobiotix
15 May 24
Current report (foreign)
4:15pm
6-K
NBTX
Nanobiotix
14 May 24
NANOBIOTIX Announces US FDA Protocol Acceptance for New Randomized Phase 2 Study Evaluating NBTXR3 for Patients with Stage Three Lung Cancer
4:15pm
6-K
NBTX
Nanobiotix
24 Apr 24
NANOBIOTIX Provides Business Update and Reports Full Year 2023 Financial Results
4:49pm
20-F
2023 FY
NBTX
Nanobiotix
Annual report (foreign)
24 Apr 24
4:23pm
6-K
atg877d u6
17 Apr 24
Current report (foreign)
4:15pm
6-K
35j6f5wa aqc
10 Apr 24
Voting Rights and Shares Capital of the Company
4:15pm
6-K
rk2xhbezy88qyz7
2 Apr 24
Current report (foreign)
4:15pm
6-K
rxeyt4ur
6 Mar 24
Nanobiotix to Present at Upcoming Investor Conferences in March
4:15pm
6-K
5ca5g9c0
13 Feb 24
Voting Rights and Shares Capital of the Company
4:15pm
6-K
fyuvudzfi07t3 war7c
31 Jan 24
Nanobiotix to Present at the Guggenheim 6th Annual Biotechnology Conference
4:15pm
6-K
zf96mx9g7
29 Jan 24
Nanobiotix Announces Achievement of $20M Development Milestone Payment Related to Ongoing Global Phase 3 Head and Neck Cancer Study
4:15pm
6-K
i1ft 04ik1os
11 Jan 24
Voting Rights and Shares Capital of the Company
5:50pm
6-K
fvm9y lcsibsil7gw
26 Dec 23
Nanobiotix Partner LianBio Assigns Its Development and Commercialization Rights for NBTXR3 in China and Other Asian Markets
6:05am
6-K
gq79jv85oma
13 Dec 23
Voting Rights and Shares Capital of the Company
4:15pm
6-K
mfnfxrbrgzewqlc2e
4 Dec 23
Current report (foreign)
4:32pm
6-K
zqwzz3gl7a
13 Nov 23
NANOBIOTIX Provides Third Quarter 2023 Operational and Financial Update
4:15pm
6-K
6pi1psnbg t62x
9 Nov 23
Current report (foreign)
4:15pm
6-K
8rbj7p6p0rpgdgufzt85
9 Nov 23
Voting Rights and Shares Capital of the Company
9:00am
6-K
oq9h 9xcr6ztchtvy3ea
8 Nov 23
NANOBIOTIX Announces Closing of Global Offering
7:53am